425: Boston Scientific to Acquire Penumbra for $14.5B

Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc. for an enterprise value of approximately $14.5 billion, expanding its cardiovascular and neurovascular portfolios.

Summary

• Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. for an enterprise value of approximately $14.5 billion.
• The transaction values each Penumbra share at $374, with stockholders having the option to elect cash or Boston Scientific common stock, subject to proration.
• The total transaction consideration will be paid approximately 73% in cash and 27% in Boston Scientific common stock.
• Boston Scientific expects to finance the approximately $11 billion cash portion of the transaction with a combination of cash on hand and new debt.
• Penumbra anticipates fourth quarter reported revenue growth in the range of approximately 21.4% 22.0% and full year 2025 reported revenue of approximately $1.4 billion, representing growth of 17.3% 17.5% over the prior fiscal year.
• The acquisition is expected to be $0.06-$0.08 dilutive to Boston Scientific's adjusted earnings per share in the first full year following the close, neutral to slightly accretive in the second year, and more accretive thereafter.
• The transaction is expected to be completed in 2026, pending Penumbra's stockholder approval and other customary closing conditions.

Sentiment

Score: 8

Explanation: The acquisition is a strong strategic move for Boston Scientific, expanding its presence in high-growth, innovative medical technology segments. While there is an initial dilutive impact on EPS, the long-term revenue and margin enhancement potential, coupled with Penumbra's robust growth and strong product portfolio, indicates a positive outlook for value creation.

Positives

• Expands Boston Scientific's cardiovascular portfolio and provides scaled entry into mechanical thrombectomy and neurovascular, which are key strategic adjacencies.
• Targets new, fast-growing segments within the vascular space, addressing the increasing prevalence of vascular diseases.
• Expected to enhance Boston Scientific's revenue and margins over time with proven offerings that have a history of growth and innovation.
• Penumbra's preliminary Q4 2025 reported revenue growth is strong, estimated at 21.4% 22.0%.
• Penumbra's preliminary full year 2025 reported revenue is approximately $1.4 billion, with growth of 17.3% 17.5% over 2024.
• Penumbra's estimated FY 2025 gross margin is high at 67.9% 68.1%, and operating margin is 13.3% 13.6%.
• Adam Elsesser, Penumbra's Chairman and CEO, will join Boston Scientific's board of directors upon close, bringing experienced leadership.
• Penumbra's portfolio and pipeline show a Weighted Average Market Growth Rate (WAMGR) of 11% in high-growth adjacent areas.

Negatives

• The transaction is expected to be $0.06-$0.08 dilutive to Boston Scientific's adjusted earnings per share in the first full year following the close of the acquisition.
• The impact to GAAP earnings per share is expected to be dilutive in the first full year following the close, and less dilutive or increasingly accretive thereafter, due to amortization expense and acquisition-related net charges.

Risks

• Economic conditions, including the impact of foreign currency fluctuations.
• Future U.S. and global political, competitive, reimbursement, and regulatory conditions, including changing trade and tariff policies.
• Geopolitical events.
• Manufacturing, distribution, and supply chain disruptions and cost increases.
• Disruptions caused by cybersecurity events.
• Disruptions caused by public health emergencies or extreme weather or other climate change-related events.
• Labor shortages and increases in labor costs.
• Variations in outcomes of ongoing and future clinical trials and market studies.
• New product introductions.
• Expected procedural volumes.
• The ability to achieve the anticipated benefits of the proposed transaction and successfully integrate Penumbra's operations.
• Business disruptions (including disruptions in relationships with employees, customers, or suppliers) following the announcement and/or closing of the proposed transaction.
• Demographic trends.
• Intellectual property issues.
• Litigation.
• Financial market conditions.
• Future business decisions made by Boston Scientific and its competitors.
• The conditions to the completion of the proposed transaction, including the receipt of the required regulatory approvals and clearances, may not be satisfied at all or in a timely manner.
• The closing of the proposed transaction may not occur or may be delayed.

Future Outlook

The transaction is expected to be completed in 2026, subject to Penumbra's stockholder approval and customary closing conditions, including regulatory approvals. Boston Scientific anticipates the acquisition to be $0.06-$0.08 dilutive to adjusted earnings per share in the first full year post-close, becoming neutral to slightly accretive in the second year and more accretive thereafter. GAAP earnings per share are expected to be dilutive initially, becoming less dilutive or increasingly accretive over time.

Management Comments

• Mike Mahoney, Chairman and CEO of Boston Scientific, stated: "This acquisition offers Boston Scientific an opportunity to enter new, fast-growing segments within the vascular space. I'm thrilled to combine the talents and shared values of our teams including welcoming Penumbra's chairman and chief executive officer, Adam Elsesser, to our board of directors upon close. The addition of Penumbra can expand access for these novel technologies to more patients and customers around the world, further enhancing our revenue and margins over time with proven offerings that have a history of growth and innovation."
• Adam Elsesser, Chairman and CEO of Penumbra, commented: "Our decades-long development of therapies for challenging medical conditions has focused on deep innovation for complex diseases so that we can offer physicians novel solutions to transform patient care. I am grateful for the amazing people who have contributed to this work and look forward to uniting our efforts and shared values as we come together with Boston Scientific."

Industry Context

This acquisition positions Boston Scientific to capitalize on the growing global prevalence of cardiovascular diseases, which are a leading cause of death. By acquiring Penumbra, Boston Scientific gains a scaled entry into the rapidly expanding mechanical thrombectomy and neurovascular markets, which are critical strategic adjacencies. Penumbra's innovative portfolio, including devices for pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack, and aneurysms, aligns with the broader industry trend towards advanced, minimally invasive solutions for complex vascular conditions. This move enhances Boston Scientific's competitive standing in these high-growth segments.

Comparison to Industry Standards

• The filing does not provide specific comparisons to global benchmarks or detailed results of comparable companies or projects within the industry.

Management Changes

Stakeholder Impact

• Shareholders (Boston Scientific): Expected long-term revenue and margin enhancement, strategic expansion into high-growth markets, but initial dilution to adjusted and GAAP EPS.
• Shareholders (Penumbra): Will receive $374 per share in cash or Boston Scientific stock, representing a significant valuation for their holdings.
• Employees (Penumbra): Integration into a larger global medical technology company, potentially offering new opportunities, but also the inherent risks of business disruptions during integration.
• Customers/Physicians: Expanded access to a broader portfolio of innovative medical technologies, particularly in cardiovascular and neurovascular interventions.
• Patients: Increased availability and access to advanced therapies for a range of complex vascular diseases, including stroke, pulmonary embolism, and acute limb ischemia.

Next Steps

• Boston Scientific will file a registration statement on Form S-4, including a proxy statement/prospectus, with the SEC.
• Penumbra will mail the proxy statement/prospectus to its stockholders.
• Penumbra stockholders will vote on the proposed transaction.
• Obtain required regulatory approvals and clearances for the transaction.
• Finalize the nature of the new debt to finance the cash portion of the acquisition.
• Integrate Penumbra's operations into Boston Scientific following the close of the transaction.

Key Dates

Recommendation

The acquisition of Penumbra is a highly strategic and transformative move for Boston Scientific, providing immediate scale and entry into high-growth, innovative segments of the vascular and neurovascular markets. While the initial EPS dilution is a factor, Penumbra's strong revenue growth, high margins, and robust product pipeline suggest significant long-term value creation. The strategic fit and potential for market leadership in critical medical areas outweigh the short-term financial adjustments, making this a compelling long-term investment.

Keywords

Boston Scientific, Penumbra, Acquisition, Medical Technology, Cardiovascular, Neurovascular, Thrombectomy, Embolization, Stroke, Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Medical Devices, Healthcare, M&A